Featured Research

from universities, journals, and other organizations

Farnesyl Transferase Inhibitor Can Help Patients At High-risk For Developing AML

Date:
December 16, 2004
Source:
University Of Texas M. D. Anderson Cancer Center
Summary:
An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).

An oral targeted therapy gentle enough to be used by patients in their 70s or 80s is showing benefit in treating high-risk myelodysplastic syndrome (MDS), a pre-leukemic disorder that can progress to acute myelogenous leukemia (AML), according to a study presented at the annual meeting of the American Society of Hematology (ASH).

Related Articles


The drug R115777 (Zarnestra) (tipifarnib) produced responses that ranged from complete responses to improvement in blood counts in about one-third of 82 patients treated at seven different hospitals in the United States, Canada, and Europe, says the study’s lead investigator, Razelle Kurzrock, M.D., a professor in the Department of Experimental Therapeutics at M. D. Anderson Cancer Center.

That level of response, as well as side effects that are well tolerated, can be a boon to the mostly elderly patients who develop the syndrome, Kurzrock says. “It is one more drug that can be tried to help improve blood counts and prevent leukemia development in these patients,” she says.

At the time the study began, there was no approved therapy to treat MDS, but recently, the FDA approved use of azacytidine (Vidaza), which is a chemotherapy drug administered subcutaneously. Zarnestra helps about as many patients as Vidaza, “but for diseases like this, you need more than one drug because the syndrome is made up of numerous subtypes,” Kurzrock says. “If one drug doesn’t help, then the other might; or they could potentially be used together.”

Zarnestra belongs to a group of drugs known as farnesyl transferase inhibitors, which block enzymes needed for the activation of cancer-promoting proteins. While the drug was initially believed to act primarily on the ras gene, which is mutated in about 25 percent of MDS patients, recent studies including this one demonstrate that patients whose ras gene is normal can benefit, Kurzrock says. “It has become apparent that Zarnestra regulates other important cancer genes, although we don’t know which ones they are.”


Story Source:

The above story is based on materials provided by University Of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas M. D. Anderson Cancer Center. "Farnesyl Transferase Inhibitor Can Help Patients At High-risk For Developing AML." ScienceDaily. ScienceDaily, 16 December 2004. <www.sciencedaily.com/releases/2004/12/041206205437.htm>.
University Of Texas M. D. Anderson Cancer Center. (2004, December 16). Farnesyl Transferase Inhibitor Can Help Patients At High-risk For Developing AML. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2004/12/041206205437.htm
University Of Texas M. D. Anderson Cancer Center. "Farnesyl Transferase Inhibitor Can Help Patients At High-risk For Developing AML." ScienceDaily. www.sciencedaily.com/releases/2004/12/041206205437.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Just A Half-Hour Of Lost Sleep Could Lead To Weight Gain

Just A Half-Hour Of Lost Sleep Could Lead To Weight Gain

Newsy (Mar. 6, 2015) A new study found losing just half an hour of sleep could make you gain weight. Video provided by Newsy
Powered by NewsLook.com
Suicide Rates Up For Young Women In U.S.

Suicide Rates Up For Young Women In U.S.

Newsy (Mar. 6, 2015) According to a report from the CDC, suicide rates among young women increased from 1994 to 2012 while rates among young men have decreased. Video provided by Newsy
Powered by NewsLook.com
Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Liberia Releases Last Ebola Patient, But Threat Remains

Liberia Releases Last Ebola Patient, But Threat Remains

Newsy (Mar. 5, 2015) Liberia&apos;s last Ebola patient has been released, and the country hasn&apos;t recorded a new case in a week. However, fears of another outbreak still exist. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins